Table of Contents
Volume 5 | Issue 2
Publication Date: July 2005- Abstract
- No Access
- Pay-Per View
- Full Text
- Add to Cart
Editorial | ||
80-81 |
Adjuvant Therapy: New Treatment Options with Oxaliplatin-Based Chemotherapy Edward Chu |
|
Researches in Brief | ||
83-85 |
Recent Data with Oxaliplatin-Containing Regimens in the Adjuvant Treatment of Colorectal Cancer G. Kesava Reddy, Edward Chu |
|
86-88 |
Adjuvant Irinotecan Regimens in Combination with Infusional 5-Fluorouracil/Leucovorin Fail to Improve Outcomes in Surgically Resected Colorectal Cancer Preeta Tyagi, Edward Chu |
|
Comprehensive Review | ||
89-100 |
Capecitabine Versus Continuous-Infusion 5-Fluorouracil for Colorectal Cancer: A Retrospective Efficacy and Safety Comparison M. Wasif Saif |
|
Original Contributions | ||
101-107 |
Capecitabine/Oxaliplatin, a Safe and Active First-Line Regimen for Older Patients with Metastatic Colorectal Cancer: Post Hoc Analysis of a Large Phase II Study Chris J. Twelves, Charles A. Butts, Jim Cassidy, Thierry Conroy, Filippo de Braud, Eduardo Díaz-Rubio, Josep M. Tabernero, Patrick Schöffski, Arie Figer, René Brunet, Johannes Grossmann, Alberto F. Sobrero, Eric J. Van Cutsem, on behalf of the XELOX investigators |
|
108-113 |
Changing Patterns of Bone and Brain Metastases in Patients with Colorectal Cancer Mark L. Sundermeyer, Neal J. Meropol, André Rogatko, Hao Wang, Steven J. Cohen |
|
114-118 |
Tumor Response to Neoadjuvant Chemoradiation Therapy for Rectal Adenocarcinoma Is Mediated by p53-Dependent and Caspase 8–Dependent Apoptotic Pathways Scott T. Kelley, Domenico Coppola, Timothy Yeatman, Jorge Marcet |
|
119-123 |
Assessment of Infusional 5-Fluorouracil Schedule and Dose Intensity: A Southwest Oncology Group and Eastern Cooperative Oncology Group Study Cynthia G. Leichman, Jacqueline K. Benedetti, Mark M. Zalupski, Howard Hochster, Anthony F. Shields, Heinz-Josef Lenz, James L. Wade III, James D. Bearden III, John S. Macdonald |
|
Translational Medicine | ||
124-131 |
Gene Polymorphisms of Epidermal Growth Factor Receptor and its Downstream Effector, Interleukin-8, Predict Oxaliplatin Efficacy in Patients with Advanced Colorectal Cancer Wu Zhang, Jan Stoehlmacher, David J. Park, Dongyun Yang, Erin Borchard, Ji Gil, Denice D. Tsao-Wei, Jim Yun, Michael Gordon, Oliver A. Press, Katrin Rhodes, Susan Groshen, Heinz-Josef Lenz |
|
Brief Communication | ||
132-135 |
Selenium Protects Against Toxicity Induced by Anticancer Drugs and Augments Antitumor Activity: A Highly Selective, New, and Novel Approach for the Treatment of Solid Tumors Marwan Fakih, Shousong Cao, Farukh A. Durrani, Youcef M. Rustum |
|
Clinical Trials | ||
136 |
Selected Clinical Trials in Colorectal Cancer CIG Media Group |
|